Phase 1 dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Park, Se Hoon ^a   Bang, Soo Mee ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a   Lee, Woon K I ^a   Chung, Min ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; UFT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INFUSION; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; STOMACH CANCER; STOMATITIS; CARCINOMA; COHORT ANALYSIS; DOSE RESPONSE; MIDDLE AGED; STOMACH TUMOR; TIME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TAXOIDS; TIME FACTORS;

EID: 26844507427     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-87     Document Type: Article

References (21)

1. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002, 34:77-83.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163-168.
4. Murad AM: Chemotherapy for Advanced Gastric Cancer: Focus on New Agents and Combinations. Cancer Control 1999, 6:361-368.
5. Seifert P, Baker LH, Reed ML, Vaitkevicius VK: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975, 36:123-128.
6. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989, 7:425-432.
7. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994, 12:412-416.
8. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003, 21:54-59.
9. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semi-synthetic analogue of taxol. J Natl Cancer Inst 1991, 83:288-291.
10. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994, 70:380-383.
11. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996, 13:87-93.
12. Burris HA 3rd: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Williston Park) 1997, 11:50-52.
13. Ando M, Watanabe T, Sasaki Y, Ying DF, Omuro Y, Katsumata N, Narabayashi M, Tokue Y, Fujii H, Igarashi T, Wakita H, Ohtsu T, Itoh K, Adachi I, Taguchi T: A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1998, 77:1937-1943.
14. Van Den Neste E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M: A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 2000, 6:64-71.
15. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon JL, Lopez-Vivanco G, Jacques C, Stenger P, Zuber E, Misset JL: Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 2003, 22:257 (abstr 1032).
16. Park SH, Kim MJ, Chung M, Lee WK, Bang SM, Cho EK, Shin DB, Lee JH: Interim analysis from a prospective randomized trial of taxanes plus 5-FU in advanced gastric cancer. Proc Am Soc Clin Oncol 2004, 22:361 (abstr 4191).
17. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18:3558-3585.
18. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990, 8:147-159.
19. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F: 5-Fluorouracil as protracted continuous intravenous infusion can be added to fulldose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 2004, 15:759-764.
20. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann A: Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003, 22:249 (abstr 999).
21. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P: Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study. J Clin Oncol 2005, 23:494-501.